2000-05-26_PERMIT FILE - M2000002

• Permit No: M2000002
• IBM Index Class Name: Permit File
• Doc Date: 5/26/2000
• Doc Name: CONTENTS
• Media Type: D
• Archive: No

/ .u o ID~303-312-7018 MAY 26'00 14 52 No.002 P.02
DIISOPROPYL METHYLPHOSPHIj~E III IIIIII I II IIII III ~ xl
CONTENTS ~ ^1 ~~
FOREWORD ........................................................................... v
CUNTRIRLITORS ..................................................................... vii
PEER REV11;W .........................................................................ix
LIST OF FIGURES ..................................................................... xv
LIST OF TAHLHS .................................................................... xvii
1, PUBLIC HY.'ALTH STATEMENT .......................................................
1.1 WHAT IS DIISOPROFYL METHYLI'HOS1'HONA'I'F.? ............................... 1
1.2 WHAT HAPPENS TO DIISOPROPYLMET1iYLPHOSPHONATP. WHF?N Il' 1?N'I'F?RS
THE ENVIRONMENT'1 .......................................................... 2
1.3 HOW M1GH'I' I BE EXPOSED TO Di150PROPYL ML•TI IYLPIiUSPHONATE? .......... 3
1.4 HOW CAN f)IISOPROPYL METIPi'LPIiOSPHONATE ENTER ANl)1.F.A VI? MY
BODY? ....................................................................... 3
e 1.5 HOW CAN DIISOPROPYL METiiYLPIIOSPHUNATE AFFECT MY HEALTH? .......... 4
1.G IS THERE A MEDICAL TY_S'I"TO ])]?'fERMINE WHETIIER I HAVE BEEN EXPOSED
TO DIISOPROPYL MFTHYLI'HUSI'HONA'fH'! ..................................... 5
1.7 WHAT RF.COMMENDATTONS HAS THE FEDERAL GOVERNMENT MnD>r TO
PROTECT HUMAN HEALTH? ........... . ...... ...........
...................... 5
].8 WHER); CAN I GET MORE WFORMATION? ...................................... 6
2. HEALTH EF}F:C'fS ................................................... ................ 9
2.1 INTRODUCTION ............................................... ................ 9
2.2 ll1SCUSSION OP HEALTH TiFPJ?CTS T1Y ROUTL' OF L'XPUSURP... _ .. . ............... 9
2.2.1 Inhalation Exposure ....................................... ............... I1
2.z.1.1 n~.~tn ........................................... ............... 11
2.2.1.2 Systemic Effects .................................. ............... 11
2.2.1.3 ]mmunolugictl and l.ymphorct.icular hffais ............ ............... 11
2.2.1.4 Neurological Effec:te ............................... ............... 11
2.2.1.5 Kcproduclive Effects .............................. ............... 1l
2.2.1 .G DevelopntenlalEffects ............................. ............... I1
2.2.1.7 Genotoxic Effects ................................. ............... 11
2.2.1.8 Cancer .......................................... ............... 11
2.2.2 OralF.xPosurc ... ................... . .................. ............... 11
2.2.2.1 Death ........................................... ............... 24
2.2.2.2 Systemic Effec;ts .................................. ............... 28
2.2.2.3 immunological and Lymphoreticular Effects ............ ............... 37
2.2.2.4 Neurological Effects ............................... ............... 38
2.2.2.5 RcpruiluclivcN.ffcc;tx .............................. ............... 40
2.2.2.G Developntentrl F-.ffa:ts ..................... . ....... ............... 42
2.2.2.7 ccnc~tuxic tiffcct+ ................................. ................43
2.2.2.8 Cana:r .......................................... ............... 43